CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported revenue of $4.02B in its most recent fiscal year, down 0.9% on the year before. It kept -3.6% of that as net income, and generated $518.49M of free cash flow. Figures below are compared against other companies classified under Services-Commercial Physical & Biological Research.
Grades vs. industry
Growth
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Revenue growth (YoY) Latest fiscal year revenue vs. the year before. | -0.9% | -0.0% | 5 / 8 |
Revenue growth (3y) Annualized revenue growth over three fiscal years. | 0.3% | 1.2% | 5 / 8 |
Revenue growth (5y) Annualized revenue growth over five fiscal years. | 6.5% | 7.5% | 5 / 7 |
EPS growth (YoY) Diluted EPS vs. the prior fiscal year. | -1555.0% | 12.8% | 6 / 6 |
EPS growth (3y) Annualized diluted EPS growth over three fiscal years. | Not reported | 28.0% | — |
EPS growth (5y) Annualized diluted EPS growth over five fiscal years. | Not reported | — | — |
Free cash flow growth (YoY) Operating cash flow less capital expenditure, vs. prior year. | 3.4% | -3.0% | 2 / 5 |
Free cash flow growth (3y) Annualized free cash flow growth over three fiscal years. | 20.7% | 20.7% | 3 / 5 |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Profitability
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Gross margin Gross profit as a share of revenue. Often unreported. | Not reported | — | — |
Operating margin Operating income as a share of revenue. | 0.6% | 9.4% | 6 / 8 |
Net margin Net income as a share of revenue. | -3.6% | 5.6% | 6 / 8 |
Free cash flow margin Free cash flow as a share of revenue. | 12.9% | 11.5% | 2 / 7 |
Return on equity Net income divided by shareholder equity. | -4.6% | 11.7% | 6 / 8 |
Return on assets Net income divided by total assets. | -2.0% | 3.0% | 6 / 8 |
Return on invested capital After-tax operating profit over debt plus equity less cash. | 0.4% | 6.3% | 5 / 6 |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Financial health
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Debt to equity Total debt divided by shareholder equity. | 0.68x | — | — |
Current ratio Current assets over current liabilities. | 1.29x | 1.19x | 4 / 8 |
Quick ratio Current assets excluding inventory, over current liabilities. | 1.02x | 1.06x | 5 / 8 |
Interest coverage Operating income divided by interest expense. | 0.24x | 2.62x | 5 / 6 |
Net debt to EBITDA Net debt over derived EBITDA. EBITDA is not a GAAP tag; it is computed. | 4.49x | 2.59x | 6 / 6 |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Debt figures can be understated where a filer splits borrowings across XBRL tags this site does not match.
Insider activity
Trades reported by officers, directors and 10% shareholders on SEC Form 4. 1 of the last 40 reported transactions were open-market purchases; the rest are mostly sales and compensation.
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 5, 2026 | Parisotto Shannon M CEVP, Disc & Safety Assessment | Open-market sale | 981 | $308.44 | $302.6K |
| Oct 5, 2026 | Parisotto Shannon M CEVP, Disc & Safety Assessment | Option exercise | 981 | $208.44 | $204.5K |
| Oct 5, 2026 | Parisotto Shannon M CEVP, Disc & Safety Assessment | Option exercise(derivative) | 981 | $0.00 | $0.00 |
| Sep 30, 2026 | Coleman Glenn EVP & Chief Financial Officer | Open-market purchase | 10 | $297.43 | $3.0K |
| Aug 25, 2026 | FOSTER JAMES C Director | Open-market sale | 33,561 | $300.00 | $10.07M |
| Aug 25, 2026 | FOSTER JAMES C Director | Option exercise | 21,132 | $194.12 | $4.10M |
| Aug 25, 2026 | FOSTER JAMES C Director | Option exercise | 12,429 | $208.44 | $2.59M |
| Aug 25, 2026 | FOSTER JAMES C Director | Option exercise(derivative) | 21,132 | $0.00 | $0.00 |
| Aug 25, 2026 | FOSTER JAMES C Director | Option exercise(derivative) | 12,429 | $0.00 | $0.00 |
| Aug 19, 2026 | Parisotto Shannon M CEVP, Disc & Safety Assessment | Open-market sale | 2,039 | $294.12 | $599.7K |
| Aug 19, 2026 | Parisotto Shannon M CEVP, Disc & Safety Assessment | Option exercise | 2,039 | $194.12 | $395.8K |
| Aug 19, 2026 | Parisotto Shannon M CEVP, Disc & Safety Assessment | Option exercise(derivative) | 2,039 | $0.00 | $0.00 |
| Aug 19, 2026 | Girshick Birgit Chief Executive Officer | Gift | 528 | $0.00 | $0.00 |
| Aug 18, 2026 | Andrews Nancy C Director | Open-market sale | 573 | $285.24 | $163.4K |
| Aug 18, 2026 | Andrews Nancy C Director | Option exercise | 573 | $164.30 | $94.1K |
| Aug 18, 2026 | Andrews Nancy C Director | Option exercise(derivative) | 573 | $0.00 | $0.00 |
| Aug 11, 2026 | Girshick Birgit Chief Executive Officer | Open-market sale | 6,500 | $279.90 | $1.82M |
| Aug 11, 2026 | Girshick Birgit Chief Executive Officer | Option exercise | 6,500 | $179.66 | $1.17M |
| Aug 11, 2026 | Parisotto Shannon M CEVP, Disc & Safety Assessment | Open-market sale | 3,714 | $279.66 | $1.04M |
| Aug 11, 2026 | Parisotto Shannon M CEVP, Disc & Safety Assessment | Option exercise | 3,714 | $179.66 | $667.3K |
| Aug 11, 2026 | Parisotto Shannon M CEVP, Disc & Safety Assessment | Option exercise(derivative) | 3,714 | $0.00 | $0.00 |
| Aug 11, 2026 | Girshick Birgit Chief Executive Officer | Option exercise(derivative) | 6,500 | $0.00 | $0.00 |
| Aug 10, 2026 | FOSTER JAMES C Director | Open-market sale | 28,733 | $275.00 | $7.90M |
| Aug 10, 2026 | FOSTER JAMES C Director | Option exercise | 28,733 | $179.66 | $5.16M |
| Aug 10, 2026 | FOSTER JAMES C Director | Option exercise(derivative) | 28,733 | $0.00 | $0.00 |
A dash under price or value means none was reported, which is normal for grants and gifts — it does not mean the shares were free. Option exercises and awards are compensation arriving on a schedule, not a judgement about the stock.
Annual financials
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B |
| Operating income | $25.16M | $227.35M | $617.26M | $650.98M | $589.86M | $432.73M | $351.15M | $331.38M | $288.28M | $237.55M |
| Net income | -$144.34M | $22.20M | $474.62M | $486.23M | $390.98M | $364.30M | $252.02M | $226.37M | $123.36M | $154.76M |
| EPS (diluted) | -$2.91 | $0.20 | n/c | n/c | n/c | n/c | n/c | n/c | n/c | n/c |
| Operating cash flow | $737.65M | $734.58M | $683.90M | $619.64M | $760.80M | $546.58M | $480.94M | $441.14M | $318.07M | $316.90M |
| Capital expenditure | $219.15M | $232.97M | $318.53M | $324.73M | $228.77M | $166.56M | $140.51M | $140.05M | $82.43M | $55.29M |
| Free cash flow | $518.49M | $501.61M | $365.37M | $294.91M | $532.03M | $380.01M | $340.42M | $301.09M | $235.64M | $261.61M |
| Total assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B |
| Shareholder equity | $3.16B | $3.46B | $3.60B | $2.98B | $2.53B | $2.11B | $1.63B | $1.32B | $1.05B | $836.77M |
| Total debt | $2.14B | $2.24B | $2.65B | $2.71B | $2.66B | $1.98B | $1.89B | $1.65B | $1.12B | $1.21B |
| Cash | $213.77M | $194.61M | $276.77M | $233.91M | $241.21M | $228.42M | $238.01M | $195.44M | $163.79M | $117.63M |
A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.
n/c marks per-share figures that are not comparable. Companies report each year as their filings stated it, and an annual report restates only its two prior years — so after a stock split, older years remain on the pre-split share count. Totals above are unaffected.
Source
Figures come from CHARLES RIVER LABORATORIES INTERNATIONAL, INC.’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 10-K filed Feb 18, 2026. View filings on EDGAR.